The Patent Finder

Neuromolecular, Inc.

Also on record
Records under this name other than the patents Neuromolecular, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.

Back to Neuromolecular, Inc.

PatentTitleStatus Expires Confidence
US 8,168,209Method and Composition for Administering an Nmda Receptor Antagonist to a Subject
Formerly held
Term ended
Term ended Jul 18, 2026 · High confidence
Term endedTerm ended Jul 18, 2026High confidence
US 7,619,007Method and Composition for Administering an Nmda Receptor Antagonist to a Subject
Term ended
Ended no later than Nov 22, 2025 · Medium confidence
Term endedEnded no later than Nov 22, 2025Medium confidence
US 8,173,708Method and Composition for Administering an Nmda Receptor Antagonist to a Subject
Formerly held
Term ended
Term ended Nov 22, 2025 · Medium confidence
Term endedTerm ended Nov 22, 2025Medium confidence
US 8,283,379Methods and Compositions for the Treatment of Cns-Related Conditions
Term ended
Term ended Nov 22, 2025 · Medium confidence
Term endedTerm ended Nov 22, 2025Medium confidence
US 8,293,794Methods and Compositions for the Treatment of Cns-Related Conditions
Term ended
Term ended Nov 22, 2025 · Medium confidence
Term endedTerm ended Nov 22, 2025Medium confidence
US 8,329,752Composition for Administering an Nmda Receptor Antagonist to a Subject
Formerly held
Term ended
Ended no later than Nov 22, 2025 · Medium confidence
Term endedEnded no later than Nov 22, 2025Medium confidence
US 8,338,485Compositions for the Treatment of Cns-Related Conditions
Formerly held
Term ended
Ended no later than Nov 22, 2025 · Medium confidence
Term endedEnded no later than Nov 22, 2025Medium confidence
US 8,338,486Methods for the Treatment of Cns-Related Conditions
Formerly held
Term ended
Ended no later than Nov 22, 2025 · Medium confidence
Term endedEnded no later than Nov 22, 2025Medium confidence
US 8,362,085Method for Administering an Nmda Receptor Antagonist to a Subject
Formerly held
Term ended
Ended no later than Nov 22, 2025 · Medium confidence
Term endedEnded no later than Nov 22, 2025Medium confidence
US 8,426,472Method and Composition for Administering an NMDA Receptor Antagonist to a Subject
Formerly held
Term ended
Term ended Nov 22, 2025 · Medium confidence
Term endedTerm ended Nov 22, 2025Medium confidence
10 of 17 patents shown.
Pro members see all 17.
Pro members: see all 17 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited